We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Glass bead game

21 June 2010 By Robert Cyran

Specialty U.S. drug group Valeant is paying a 15 percent premium for Canadian rival Biovail yet the latter’s shareholders end up with a majority of the merged group. Strategy and tax considerations may explain the deal. But Biovail s checkered past invites questions.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)